Emergent BioSolutions, Inc. Quarterly Results: Standalone & Consolidated Reports

Quarterly Results

Results Snapshot

YoYQoQ

Figures in Million

Consolidate Quarterly Results

Dec'25

Sep'25

Jun'25

Mar'25

Dec'24

Sep'24

Jun'24

Net Sales

148.70

231.10

140.90

222.20

194.70

293.80

254.70

Other Operating Income

0.00

Total Operating income

148.70

231.10

140.90

222.20

194.70

293.80

254.70

Raw Material Cost

102.10

102.00

83.40

105.70

134.70

133.90

309.20

Purchase of Finished goods

0.00

(Increase) / Decrease In Stocks

0.00

Employee Cost

0.00

Power Cost

0.00

Manufacturing Expenses

14.70

15.20

14.70

14.80

8.30

23.60

Selling and Distribution Expenses

51.10

38.80

44.00

52.70

60.70

75.90

77.30

Other Expenses

-0.26

-0.17

0.05

-0.56

0.49

0.37

Total Expenditure (Excl Depreciation)

165.30

154.30

140.40

173.60

204.60

223.00

413.80

Operating Profit (PBDIT) excl Other Income

-16.599999999999998

76.8

0.5

48.6

-9.9

70.8

-159.1

Other Income

5.20

-3.70

57.50

-3.30

86.20

-42.70

Operating Profit (PBDIT)

12.10

96.90

20.80

132.10

12.80

184.10

-172.40

Interest

14.70

15.20

14.70

14.80

8.30

23.60

Exceptional Items

-24.60

-0.30

1.10

1.30

0.40

-6.30

-44.40

Gross Profit (PBDT)

46.60

129.10

57.50

116.50

60.00

159.90

-54.50

Depreciation

23.50

23.80

24.00

26.00

27.10

29.40

Profit Before Tax

-50.70

57.60

-16.80

92.70

-27.60

142.40

-269.80

Tax

3.90

6.40

-4.80

24.70

3.70

27.60

13.30

Provisions and contingencies

0.00

Profit After Tax

-54.60

51.20

-12.00

68.00

-31.30

114.80

-283.10

Extraordinary Items

0.00

Prior Period Expenses

0.00

Other Adjustments

0.00

Net Profit

-54.60

51.20

-12.00

68.00

-31.30

114.80

-283.10

Share in Profit of Associates

0.00

Minority Interest

0.00

Other related items

0.00

Consolidated Net Profit

-54.60

51.20

-12.00

68.00

-31.30

114.80

-283.10

Equity Capital

0.00

Face Value

0.0

Reserves

522.60

582.50

536.20

552.70

482.80

508.40

386.30

Earnings per share (EPS)

-1.04

0.91

-0.22

1.19

-0.58

2.06

-5.38

Diluted Earnings per share

-1.04

0.91

-0.22

1.19

-0.58

2.06

-5.38

Operating Profit Margin (Excl OI)

-11.16%

33.23%

0.35%

21.87%

-5.08%

24.1%

-62.47%

Gross Profit Margin

-18.29%

35.22%

5.11%

53.42%

-0.82%

57.69%

-94.39%

PAT Margin

-36.72%

22.15%

-8.52%

30.6%

-16.08%

39.07%

-111.15%

Public Share Holdings (%)

0.0%

Pledged Promotor Holding (%)

0.0%

Quarterly Analysis Highlights - QoQ

Net Sales

QoQ Growth in quarter ended Dec 2025 is -35.66% vs 64.02% in Sep 2025

Consolidate Net Profit

QoQ Growth in quarter ended Dec 2025 is -206.64% vs 526.67% in Sep 2025

Operating Profit (PBDIT) excl Other Income

QoQ Growth in quarter ended Dec 2025 is -93.14% vs 310.61% in Sep 2025

Interest

QoQ Growth in quarter ended Dec 2025 is -3.29% vs 3.40% in Sep 2025

Operating Profit Margin (Excl OI)

QoQ Growth in quarter ended Dec 2025 has fallen from Sep 2025

Compare Quarterly Results Of Emergent BioSolutions, Inc. With

Select Peers

Figures in Million

Consolidate Quarterly Results

Change(USD)

Change(%)

Net Sales

148.70

0.00

148.70

Other Operating Income

0.00

Total Operating income

148.70

0.00

148.70

Raw Material Cost

102.10

0.36

101.74

28,261.11%

Purchase of Finished goods

0.00

(Increase) / Decrease In Stocks

0.00

Employee Cost

0.00

Power Cost

0.00

Manufacturing Expenses

14.70

1.85

12.85

694.59%

Selling and Distribution Expenses

51.10

14.55

36.55

251.20%

Other Expenses

-0.26

1.91

-2.17

-113.61%

Total Expenditure (Excl Depreciation)

165.30

35.86

129.44

360.96%

Operating Profit (PBDIT) excl Other Income

-16.60

-35.86

19.26

53.71%

Other Income

5.20

3.81

1.39

36.48%

Operating Profit (PBDIT)

12.10

-31.69

43.79

138.18%

Interest

14.70

1.85

12.85

694.59%

Exceptional Items

-24.60

0.00

-24.60

Gross Profit (PBDT)

46.60

-0.36

46.96

13,044.44%

Depreciation

23.50

0.36

23.14

6,427.78%

Profit Before Tax

-50.70

-33.91

-16.79

-49.51%

Tax

3.90

-0.24

4.14

1,725.00%

Provisions and contingencies

0.00

Profit After Tax

-54.60

-33.67

-20.93

-62.16%

Extraordinary Items

0.00

Prior Period Expenses

0.00

Other Adjustments

0.00

Net Profit

-54.60

-33.67

-20.93

-62.16%

Share in Profit of Associates

0.00

Minority Interest

0.00

Other related items

0.00

Consolidated Net Profit

-54.60

-33.67

-20.93

-62.16%

Equity Capital

0.00

Face Value

0.00

Reserves

522.60

241.83

280.77

116.10%

Earnings per share (EPS)

-1.04

-0.40

-0.64

-160.00%

Diluted Earnings per share

-1.04

-0.40

-0.64

-160.00%

Operating Profit Margin (Excl OI)

-11.16%

0.00%

0.00

-11.16%

Gross Profit Margin

-18.29%

0.00%

0.00

-18.29%

PAT Margin

-36.72%

0.00%

0.00

-36.72%

Public Share Holdings (%)

0.00

0.00%

Pledged Promotor Holding (%)

0.00

0.00%

Quarterly - Net Sales

Net Sales 14.87 Million

in Dec 2025

Figures in Million

QoQ Growth in quarter ended Dec 2025 is -35.66% vs 64.02% in Sep 2025

YoY Growth in quarter ended Dec 2025 is -23.63% vs -29.61% in Dec 2024

Quarterly - Consolidate Net Profit

Consolidate Net Profit -5.46 Million

in Dec 2025

Figures in Million

QoQ Growth in quarter ended Dec 2025 is -206.64% vs 526.67% in Sep 2025

YoY Growth in quarter ended Dec 2025 is -74.44% vs 36.77% in Dec 2024

Quarterly - Operating Profit (PBDIT)

Operating Profit (PBDIT) 0.69 Million

in Dec 2025

Figures in Million

QoQ Growth in quarter ended Dec 2025 is -93.14% vs 310.61% in Sep 2025

YoY Growth in quarter ended Dec 2025 is -57.14% vs 241.23% in Dec 2024

Quarterly - Interest

Interest 1.47 Million

in Dec 2025

Figures in Million

QoQ Growth in quarter ended Dec 2025 is -3.29% vs 3.40% in Sep 2025

YoY Growth in quarter ended Dec 2025 is -0.68% vs -33.33% in Dec 2024

Quarterly - Operating Profit Margin (Excl OI)

Operating Profit Margin (Excl OI) -11.16%

in Dec 2025

Figures in %

QoQ Growth in quarter ended Dec 2025 has fallen from Sep 2025

YoY Growth in quarter ended Dec 2025 has fallen from Dec 2024